Everolimus-Associated Thrombotic Microangiopathy and Acute Kidney Injury in a Patient with Breast Cancer

Ersan S., Peker A., GÜLLE S., Yilmaz Avcioglu B.

TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, vol.25, pp.86-88, 2016 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 25
  • Publication Date: 2016
  • Doi Number: 10.5262/tndt.2016.17
  • Journal Name: TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.86-88
  • Keywords: Everolimus, Thrombotic microangiopathy, Breast cancer, HEMOLYTIC-UREMIC SYNDROME, COMBINATION
  • Dokuz Eylül University Affiliated: Yes

Abstract

Thrombotic microangiopathy is a pathological condition caused by several factors including drugs, and characterized by endothelial injury and small vessel occlusion. It may cause severe acute kidney injury. Everolimus, a mammalian target of Rapamycin inhibitor, is a macrolide antibiotic widely used in clinical conditions because of its anticancer and immunosuppressive effects. Recently it has been approved for use in breast cancer at a dose of 10 mg/day in combination with exemestane, an aromatase inhibitor. In the literature a few cases of everolimus-induced thrombotic microangiopathy and acute kidney injury in breast cancer patients have been reported. Here we reported the management of a breast cancer patient with everolimus-induced thrombotic microangiopathy and severe acute kidney injury with emphasis on close monitoring of kidney functions.